Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 16 | 2024 | 1332 | 2.560 |
Why?
|
| Brain Neoplasms | 16 | 2023 | 4868 | 1.870 |
Why?
|
| Cerebellar Neoplasms | 4 | 2022 | 434 | 1.490 |
Why?
|
| Medulloblastoma | 4 | 2021 | 541 | 1.240 |
Why?
|
| Meningioma | 2 | 2020 | 290 | 1.160 |
Why?
|
| Sarcoma, Ewing | 2 | 2020 | 406 | 1.060 |
Why?
|
| Spinal Neoplasms | 7 | 2024 | 632 | 1.010 |
Why?
|
| Neoplasms, Second Primary | 3 | 2024 | 1350 | 0.950 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 8 | 2022 | 2373 | 0.820 |
Why?
|
| Glioma | 4 | 2022 | 1971 | 0.810 |
Why?
|
| Astrocytoma | 2 | 2021 | 323 | 0.800 |
Why?
|
| Oligodendroglioma | 1 | 2021 | 106 | 0.740 |
Why?
|
| Hospitals, High-Volume | 1 | 2020 | 78 | 0.710 |
Why?
|
| Meningeal Neoplasms | 2 | 2022 | 443 | 0.690 |
Why?
|
| Bone Neoplasms | 3 | 2023 | 2578 | 0.670 |
Why?
|
| Databases, Factual | 5 | 2020 | 2236 | 0.670 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 121 | 0.650 |
Why?
|
| Cancer Care Facilities | 2 | 2020 | 884 | 0.640 |
Why?
|
| Radiotherapy | 3 | 2020 | 1827 | 0.630 |
Why?
|
| Radiotherapy Dosage | 13 | 2022 | 3846 | 0.560 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2019 | 295 | 0.530 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2019 | 506 | 0.500 |
Why?
|
| Radiation Dosage | 1 | 2019 | 1016 | 0.480 |
Why?
|
| SEER Program | 1 | 2016 | 1000 | 0.450 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 601 | 0.380 |
Why?
|
| Re-Irradiation | 2 | 2022 | 163 | 0.380 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2022 | 2107 | 0.340 |
Why?
|
| Humans | 49 | 2024 | 262350 | 0.330 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2021 | 6225 | 0.330 |
Why?
|
| Radiation Injuries | 2 | 2022 | 1412 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 10074 | 0.330 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2017 | 2233 | 0.310 |
Why?
|
| Propensity Score | 3 | 2020 | 755 | 0.290 |
Why?
|
| Combined Modality Therapy | 8 | 2023 | 8887 | 0.260 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 15708 | 0.250 |
Why?
|
| Retrospective Studies | 13 | 2024 | 38028 | 0.240 |
Why?
|
| Fractures, Compression | 1 | 2024 | 42 | 0.230 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2017 | 565 | 0.230 |
Why?
|
| Adult | 15 | 2022 | 78150 | 0.220 |
Why?
|
| Spinal Fractures | 1 | 2024 | 133 | 0.210 |
Why?
|
| Mastectomy, Segmental | 3 | 2019 | 1026 | 0.210 |
Why?
|
| Female | 23 | 2022 | 142310 | 0.210 |
Why?
|
| Proton Therapy | 1 | 2022 | 1577 | 0.210 |
Why?
|
| Chordoma | 1 | 2023 | 163 | 0.200 |
Why?
|
| Chondrosarcoma | 1 | 2023 | 216 | 0.200 |
Why?
|
| Survival Rate | 5 | 2020 | 12243 | 0.190 |
Why?
|
| Incidence | 2 | 2021 | 5712 | 0.180 |
Why?
|
| Oncologists | 1 | 2022 | 134 | 0.180 |
Why?
|
| Brain Stem Neoplasms | 1 | 2021 | 108 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2017 | 3892 | 0.180 |
Why?
|
| Spinal Cord Diseases | 1 | 2020 | 90 | 0.180 |
Why?
|
| Digestive System Neoplasms | 1 | 2020 | 82 | 0.170 |
Why?
|
| Lung Neoplasms | 5 | 2023 | 11575 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2022 | 2321 | 0.170 |
Why?
|
| Child | 6 | 2022 | 29146 | 0.170 |
Why?
|
| Glioblastoma | 2 | 2022 | 1810 | 0.170 |
Why?
|
| Middle Aged | 15 | 2024 | 86512 | 0.170 |
Why?
|
| Child, Preschool | 4 | 2022 | 16263 | 0.160 |
Why?
|
| Age Factors | 2 | 2018 | 5387 | 0.160 |
Why?
|
| Male | 16 | 2021 | 123339 | 0.160 |
Why?
|
| Kidney Neoplasms | 2 | 2022 | 3018 | 0.160 |
Why?
|
| Disease-Free Survival | 3 | 2020 | 10025 | 0.160 |
Why?
|
| Income | 1 | 2018 | 225 | 0.150 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 1751 | 0.150 |
Why?
|
| Aged | 14 | 2020 | 70370 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2023 | 33024 | 0.150 |
Why?
|
| Infant, Newborn | 2 | 2021 | 8230 | 0.150 |
Why?
|
| Proportional Hazards Models | 4 | 2023 | 5010 | 0.150 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 30000 | 0.150 |
Why?
|
| Patient Preference | 1 | 2019 | 221 | 0.150 |
Why?
|
| Margins of Excision | 1 | 2018 | 285 | 0.150 |
Why?
|
| Insurance, Health | 1 | 2018 | 251 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 293 | 0.140 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2019 | 306 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2023 | 807 | 0.140 |
Why?
|
| Sezary Syndrome | 1 | 2017 | 159 | 0.130 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 1229 | 0.130 |
Why?
|
| Emotions | 1 | 2019 | 567 | 0.130 |
Why?
|
| Craniospinal Irradiation | 1 | 2017 | 128 | 0.130 |
Why?
|
| Melanoma | 2 | 2023 | 5321 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 5339 | 0.130 |
Why?
|
| Regression Analysis | 1 | 2018 | 1550 | 0.130 |
Why?
|
| Tumor Burden | 2 | 2018 | 1991 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 383 | 0.130 |
Why?
|
| Neurosurgical Procedures | 1 | 2020 | 610 | 0.130 |
Why?
|
| Infant | 2 | 2021 | 13310 | 0.130 |
Why?
|
| Risk Factors | 3 | 2021 | 17611 | 0.120 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 13674 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2017 | 9293 | 0.120 |
Why?
|
| Young Adult | 5 | 2021 | 21506 | 0.120 |
Why?
|
| Cardiotoxicity | 1 | 2015 | 158 | 0.120 |
Why?
|
| Mycosis Fungoides | 1 | 2017 | 320 | 0.120 |
Why?
|
| Chemoradiotherapy | 3 | 2017 | 1947 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 802 | 0.110 |
Why?
|
| Sarcoma | 1 | 2024 | 1726 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 803 | 0.110 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 3482 | 0.110 |
Why?
|
| Prognosis | 5 | 2023 | 21746 | 0.110 |
Why?
|
| Logistic Models | 2 | 2016 | 3450 | 0.100 |
Why?
|
| Inpatients | 1 | 2017 | 688 | 0.100 |
Why?
|
| Brain Stem | 1 | 2022 | 175 | 0.100 |
Why?
|
| Medicare | 1 | 2016 | 896 | 0.100 |
Why?
|
| Radiologists | 2 | 2022 | 163 | 0.090 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2015 | 408 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 3757 | 0.090 |
Why?
|
| Neoplasms | 3 | 2020 | 15206 | 0.090 |
Why?
|
| Protons | 1 | 2022 | 473 | 0.090 |
Why?
|
| Particle Accelerators | 2 | 2022 | 355 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 4323 | 0.080 |
Why?
|
| United States | 4 | 2023 | 15563 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 3988 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2016 | 9198 | 0.080 |
Why?
|
| Adolescent | 4 | 2021 | 31279 | 0.070 |
Why?
|
| Time Factors | 1 | 2018 | 12983 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2016 | 6896 | 0.060 |
Why?
|
| Brain | 3 | 2022 | 4113 | 0.060 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2023 | 210 | 0.050 |
Why?
|
| Patient Selection | 2 | 2020 | 2061 | 0.050 |
Why?
|
| Radiotherapy Setup Errors | 1 | 2022 | 80 | 0.050 |
Why?
|
| Immobilization | 1 | 2022 | 93 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2022 | 7732 | 0.050 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2022 | 203 | 0.050 |
Why?
|
| Spine | 1 | 2022 | 294 | 0.050 |
Why?
|
| Patient Positioning | 1 | 2022 | 195 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 573 | 0.050 |
Why?
|
| Decision Making | 2 | 2019 | 1295 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 1002 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 14910 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2023 | 719 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2020 | 316 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 5101 | 0.040 |
Why?
|
| Models, Anatomic | 1 | 2019 | 155 | 0.040 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2019 | 226 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 63 | 0.040 |
Why?
|
| Biopsy | 2 | 2016 | 3454 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 7793 | 0.040 |
Why?
|
| Spinal Cord | 1 | 2020 | 693 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 14304 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2020 | 1033 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 15882 | 0.030 |
Why?
|
| Radiotherapy, Conformal | 1 | 2019 | 902 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 2188 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 928 | 0.030 |
Why?
|
| Radiometry | 1 | 2019 | 983 | 0.030 |
Why?
|
| Communication | 1 | 2019 | 880 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2016 | 740 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 2326 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2023 | 3352 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 2394 | 0.020 |
Why?
|
| Quality of Life | 1 | 2023 | 4579 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2022 | 12925 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 2084 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 4770 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 7580 | 0.010 |
Why?
|